LUMO vs. BIOR, GDTC, CPIX, LSTA, ONCT, BFRG, LPCN, BNTC, TXMD, and FLGC
Should you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Biora Therapeutics (BIOR), CytoMed Therapeutics (GDTC), Cumberland Pharmaceuticals (CPIX), Lisata Therapeutics (LSTA), Oncternal Therapeutics (ONCT), Bullfrog AI (BFRG), Lipocine (LPCN), Benitec Biopharma (BNTC), TherapeuticsMD (TXMD), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical preparations" industry.
Biora Therapeutics (NASDAQ:BIOR) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.
Biora Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Lumos Pharma received 30 more outperform votes than Biora Therapeutics when rated by MarketBeat users. Likewise, 77.27% of users gave Lumos Pharma an outperform vote while only 66.67% of users gave Biora Therapeutics an outperform vote.
Lumos Pharma has higher revenue and earnings than Biora Therapeutics. Lumos Pharma is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Lumos Pharma has a consensus price target of $18.00, suggesting a potential upside of 496.03%. Given Biora Therapeutics' higher possible upside, analysts plainly believe Lumos Pharma is more favorable than Biora Therapeutics.
In the previous week, Biora Therapeutics had 3 more articles in the media than Lumos Pharma. MarketBeat recorded 3 mentions for Biora Therapeutics and 0 mentions for Lumos Pharma. Lumos Pharma's average media sentiment score of 0.00 equaled Biora Therapeutics'average media sentiment score.
43.7% of Biora Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are owned by institutional investors. 23.2% of Biora Therapeutics shares are owned by insiders. Comparatively, 25.4% of Lumos Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Biora Therapeutics has a net margin of 0.00% compared to Biora Therapeutics' net margin of -1,659.39%. Lumos Pharma's return on equity of 0.00% beat Biora Therapeutics' return on equity.
Summary
Lumos Pharma beats Biora Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Lumos Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lumos Pharma Competitors List
Related Companies and Tools
